Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft

BACKGROUND: chA21 is a novel tumor-inhibitory antibody which recognized subdomain I of HER2 extracellular domain with an epitope distinct from other HER2 antibodies. Previously, we demonstrated that chA21 inhibits human ovarian carcinoma cell line SKOV-3 growth in vitro and in vivo study. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Anli, Shen, Guodong, Zhao, Ting, Zhang, Guihong, Liu, Jing, Song, Lihua, Wei, Wei, Bing, Ling, Wu, Zhengsheng, Wu, Qiang
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939608/
https://www.ncbi.nlm.nih.gov/pubmed/20723224
http://dx.doi.org/10.1186/1757-2215-3-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939608/
https://www.ncbi.nlm.nih.gov/pubmed/20723224
http://dx.doi.org/10.1186/1757-2215-3-20

Ejemplares similares